Donald Zinn

Don has 25 years of experience in building biotech, pharmaceutical and medical device companies from benchtop to the marketplace, generating and cultivating business relationships, developing and implementing business strategies, fundraising, and executing deals. Don was the US Head of Innovation for Rentschler Biopharma, CEO of Aursos and AzoRX, co-Founder of Artesian Therapeutics and Genetic Immunity. Don volunteers at the National Institutes of Health (NIH) as a Commercialization Grant Reviewer for the Commercialization Readiness Program. Don has been the VP for US Business for Crossject since the beginning of COVID, closing deals worldwide for their needle free auto-injector platform and portfolio of emergency drug device combinations.